## Abstract ## Objective The underlying effect of serotonergic neurotransmission has been implicated in several psychiatric disorders. The inability to routinely and non‐invasively determine the integrity of the serotonergic system __in vivo__ has limited our understanding of disorders with a puta
The loudness dependence auditory evoked potential is insensitive to acute changes in serotonergic and noradrenergic neurotransmission
✍ Scribed by Jessica Oliva; Sumie Leung; Rodney J. Croft; Barry V. O'Neill; Joanne O'Kane; Julie Stout; K. Luan Phan; Pradeep J. Nathan
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 112 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0885-6222
- DOI
- 10.1002/hup.1133
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
The loudness dependence of the auditory evoked potential (LDAEP) has been proposed as an electrophysiological marker for assessing serotonergic function in vivo in humans, although accumulating evidence suggests that it is insensitive to acute changes in serotonergic neurotransmission. Very little is known about the sensitivity of the LDAEP to other neurotransmitter systems including the noradrenergic system. The current study examined the effects of noradrenergic modulation as well as serotonergic modulation on the LDAEP.
Methods
The study utilised a double‐blind placebo‐controlled design in which the LDAEP in 17 healthy males and females was tested following acute administration of each of citalopram (20 mg), reboxetine (4 mg) and placebo.
Results
Neither citalopram nor reboxetine modulated the LDAEP relative to placebo treatment (p > 0.05).
Conclusion
These findings suggest that the LDAEP is insensitive to acute changes in serotonergic or noradrenergic neurotransmission and thus is a poor pharmacodynamic marker of these systems. Copyright © 2010 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract ## Objectives The loudness dependence of the auditory evoked potential (LDAEP) has been proposed as a valid means of non‐invasively assessing __in vivo__ central serotonin (5‐hydroxytryptamine, 5‐HT) function in humans. The specificity and sensitivity of the LDAEP to changes in 5‐HT ne